<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01697722</url>
  </required_header>
  <id_info>
    <org_study_id>BA21</org_study_id>
    <nct_id>NCT01697722</nct_id>
  </id_info>
  <brief_title>Real-world Effectiveness and Cost-effectiveness of HFA-beclometasone Compared With ICS/LABA Combination Therapy</brief_title>
  <acronym>QvarvsCombo</acronym>
  <official_title>A Retrospective Evaluation of Effectiveness and Cost-effectiveness of Extrafine HFA-BDP Compared With Combination ICS/LABA Therapy in the Management of Asthma in a Representative Population of UK Primary Care Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research in Real-Life Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Research in Real-Life Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness, cost-effectiveness and direct healthcare costs of&#xD;
      asthma management in patients with evidence of persistent asthma following an increase in&#xD;
      asthma therapy in the form of either an increased dose of inhaled glucocorticosteroids (ICS)&#xD;
      using extrafine hydrofluoroalkane-beclometasone dipropionate (HFA-BDP) via pressurised&#xD;
      metered-dose inhaler (pMDI) or breath-actuated inhaler (BAI), or a change to combination ICS&#xD;
      plus long-acting bronchodilator (LABA) therapy using fixed combinations (fluticasone&#xD;
      propionate / salmeterol [FP/SAL] or budesonide / formoterol [BUD/FOR]) or separate pMDIs and&#xD;
      BAIs.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current asthma guidelines in the UK are underpinned by evidence derived from randomised&#xD;
      controlled trials (RCTs). Although RCT data are considered the gold standard, the patients&#xD;
      recruited to asthma RCTs are estimated to represent less than 10% of the United Kingdom's&#xD;
      (UK's) asthma population. The poor representation of the asthma population is due to a number&#xD;
      of factors, such as tightly-controlled inclusion criteria for RCTs. There is therefore a need&#xD;
      for more representative RCTs and real-life observational studies to inform existing&#xD;
      guidelines and help optimise asthma outcomes.&#xD;
&#xD;
      The fixed combination asthma inhalers, FP/SAL (Seretide) and BUD/FOR (Symbicort) are&#xD;
      indicated for use in asthma when adequate asthma control is not achieved with low/medium dose&#xD;
      ICS therapy and as-needed (prn) reliever therapy (a short-acting beta-agonist [SABA]). Fixed&#xD;
      combination inhalers are also indicated in patients already adequately controlled on separate&#xD;
      ICS/LABA therapy. However, emerging trends in asthma prescribing indicate increasing use of&#xD;
      add-on therapies (particularly in the form of combination inhalers) in the early stages of&#xD;
      asthma therapy, even as first-line therapy.&#xD;
&#xD;
      In practice, there is significant pressure (supported by asthma guidelines) to use the least&#xD;
      expensive, effective inhaled therapies available. While the effect of increased use of add-on&#xD;
      and combination therapies in terms of patient benefits remains uncertain, the impact on the&#xD;
      UK's National Health Service (NHS) treatment costs is unequivocal.&#xD;
&#xD;
      Short, randomised trials of the effectiveness of asthma monotherapies have demonstrated that&#xD;
      extrafine HFA-BDP is at least as effective at half the dose as BDP pMDI, and equivalent to&#xD;
      same-dose FP pMDI. There is also evidence to suggest that extrafine HFA-BDP optimises&#xD;
      deposition in the lung and affords greater tolerance of poor coordination of breathing and&#xD;
      inhaler actuation. In addition, one long-term, prospective, randomised, open-labelled trial&#xD;
      comparing extrafine HFA-BDP with BDP over the course of one year demonstrated greater&#xD;
      improvements in symptom-free days and quality of life in the extrafine HFA-BDP treatment&#xD;
      group, at a lower cost per symptom-free day.&#xD;
&#xD;
      The hypothesis for this study, therefore, is that extrafine HFA-BDP may be a suitable, and&#xD;
      cost-effective, alternative to combination therapy (as fixed or separate inhalers) in&#xD;
      children and adults with evidence of persistent asthma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1991</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proxy asthma control</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>No recorded hospital attendance for asthma including admission, Accident &amp; Emergency (A&amp;E) attendance, out of hours attendance or Out-Patient Department (OPD) attendance, AND&#xD;
No prescriptions for oral steroid, AND&#xD;
No consultations, hospital admissions or A&amp;E attendance for lower respiratory tract infections (LRTI) requiring antibiotics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success of therapeutic regimen</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Defined as the absence of (i) Exacerbation:&#xD;
Unscheduled hospital admissions / A&amp;E attendance for asthma, OR&#xD;
Acute use of oral steroids&#xD;
AND&#xD;
(ii) No consultations, hospital admissions or A&amp;E attendance for LRTI requiring antibiotics&#xD;
AND&#xD;
(iii) No change in therapeutic regimen:&#xD;
Increased dose of ICS, and/or&#xD;
Change in ICS/LABA, and/or&#xD;
Change in delivery device, and/or&#xD;
Use of additional therapy as defined by: theophylline, LTRAs, oral beta agonists (or LABAs in patients receiving extrafine HFA-BDP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Success of therapeutic regimen (sensitivity - independent of cost saving)</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Success: defined as the absence of&#xD;
(i) Exacerbation:&#xD;
Unscheduled hospital admissions / A&amp;E attendance for asthma, OR&#xD;
Acute use of oral steroids&#xD;
AND&#xD;
(ii) No consultations, hospital admissions or A&amp;E attendance for lower respiratory tract infections (LRTI) requiring antibiotics&#xD;
AND&#xD;
(iii) No change in therapeutic regimen:&#xD;
Increased dose of ICS, and/or&#xD;
Use of additional therapy as defined by: theophylline, leukotreine receptor antagonists (LTRAs), oral beta agonists (or LABAs in patients receiving extrafine HFA-BDP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>average SABA daily dose during outcome year</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Average daily dose categorised as: 0mcg, &gt;0-100mcg, &gt;100-200mcg, &gt;200-400mcg, &gt;400-800mcg, &gt;800mcg).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisations</measure>
    <time_frame>One-year outcome period</time_frame>
    <description>Mean number of asthma and respiratory-related hospitalisations recorded per patient during the outcome year</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">815377</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Step-up as FDC ICS/LABA</arm_group_label>
    <description>ICS asthma patients who increased therapy as FDC ICS/LABA (no increase in daily ICS dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Step up as separate therapies</arm_group_label>
    <description>ICS asthma patients who increased therapy as ICS / LABA via separate pMDI and / or BAI inhalers (no increase in daily ICS dose).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Qvar step-up</arm_group_label>
    <description>ICS asthma patients who increased therpy as extra-fine hydrofluoroalkane-beclometasone dipropionate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Extra-fine hydrofluoroalkane-beclometasone dipropionate</intervention_name>
    <description>Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI</description>
    <arm_group_label>Qvar step-up</arm_group_label>
    <other_name>Qvar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICS / LABA via separate pMDI and / or BAI inhalers</intervention_name>
    <description>A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose</description>
    <arm_group_label>Step up as separate therapies</arm_group_label>
    <other_name>ICS+LABA separates</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care asthma patients who were receiving ICS therapy (any of BDP, extrafine BDP-HFA,&#xD;
        BUD or FP as pMDI or BAI) who, at an index prescription date, underwent either:&#xD;
&#xD;
        (i) an increase in ICS as extrafine HFA-BDP (pMDI or BAI); (ii) a change to combination&#xD;
        therapy with a separate LABA pMDI or BAI (no change in drug, device or daily BDP-equivalent&#xD;
        dose) (iii) a change to combination therapy via a fixed-combination inhaler (with no&#xD;
        increase in daily BDP-equivalent dose).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged: 4-60 years:&#xD;
&#xD;
               -  Paediatric cohort (aged 4-11 years), and&#xD;
&#xD;
               -  Adult cohort (aged 12-60 years)&#xD;
&#xD;
               -  Aged 61-80 years and never smoked for an additional elderly cohort;&#xD;
&#xD;
          -  Evidence of asthma: i.e. a diagnostic code of asthma or at least 2 asthma&#xD;
             prescriptions, including one ICS prescription, at different points in time during the&#xD;
             year prior to IPD (the baseline year)&#xD;
&#xD;
          -  Be on current asthma therapy: i.e. at least 1 asthma prescription in the year prior to&#xD;
             IPD, and at least 1 other asthma prescription during the same period&#xD;
&#xD;
          -  Have at least one year of up-to-standard (UTS) baseline data (prior to the IPD) and at&#xD;
             least one year of UTS outcome data (following the IPD).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  had a diagnostic read code for chronic obstructive pulmonary disease (COPD) at any&#xD;
             time&#xD;
&#xD;
          -  had a diagnostic read code for chronic respiratory disease at any time (other than&#xD;
             asthma)&#xD;
&#xD;
          -  any patients receiving a combination inhaler in addition to their separate ICS inhaler&#xD;
             in the baseline year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Price, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Company Director</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alison Chisholm, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Research Project Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Practice Research Database</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.optimumpatientcare.org</url>
    <description>Optimum Patient Care is the Research in Real Life's sister company (a social enterprise organisation)</description>
  </link>
  <reference>
    <citation>Herland K, Akselsen JP, Skj√∏nsberg OH, Bjermer L. How representative are clinical study patients with asthma or COPD for a larger &quot;real life&quot; population of patients with obstructive lung disease? Respir Med. 2005 Jan;99(1):11-9.</citation>
    <PMID>15672843</PMID>
  </reference>
  <reference>
    <citation>Travers J, Marsh S, Caldwell B, Williams M, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. External validity of randomized controlled trials in COPD. Respir Med. 2007 Jun;101(6):1313-20. Epub 2006 Nov 17.</citation>
    <PMID>17113277</PMID>
  </reference>
  <reference>
    <citation>Appleton SL, Adams RJ, Wilson DH, Taylor AW, Ruffin RE; North West Adelaide Cohort Health Study Team. Spirometric criteria for asthma: adding further evidence to the debate. J Allergy Clin Immunol. 2005 Nov;116(5):976-82.</citation>
    <PMID>16275363</PMID>
  </reference>
  <reference>
    <citation>Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. National Heart, Lung, and Blood Institute, National Institutes of Health, 2007. (Accessed March 2008, at http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf</citation>
  </reference>
  <reference>
    <citation>Aubier M, Wettenger R, Gans SJ. Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma. Respir Med. 2001 Mar;95(3):212-20.</citation>
    <PMID>11266239</PMID>
  </reference>
  <reference>
    <citation>Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone propionate. Ann Allergy Asthma Immunol. 2001 May;86(5):575-82.</citation>
    <PMID>11379810</PMID>
  </reference>
  <reference>
    <citation>Lasserson TJ, Cates CK, Jones AB, Steele EH, White J. Fluticasone versus HFA-beclomethasone dipropionate for chronic asthma in adults and children. Cochrane Database Syst Rev. 2006 Apr 19;(2):CD005309. Review.</citation>
    <PMID>16625634</PMID>
  </reference>
  <reference>
    <citation>Gross G, Thompson PJ, Chervinsky P, Vanden Burgt J. Hydrofluoroalkane-134a beclomethasone dipropionate, 400 microg, is as effective as chlorofluorocarbon beclomethasone dipropionate, 800 microg, for the treatment of moderate asthma. Chest. 1999 Feb;115(2):343-51.</citation>
    <PMID>10027430</PMID>
  </reference>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>September 28, 2012</study_first_submitted>
  <study_first_submitted_qc>October 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2012</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Research in Real-Life Ltd</investigator_affiliation>
    <investigator_full_name>David Price</investigator_full_name>
    <investigator_title>Professor David Price</investigator_title>
  </responsible_party>
  <keyword>Primary care</keyword>
  <keyword>Asthma management</keyword>
  <keyword>Inhaled corticosteroids</keyword>
  <keyword>Extra-fine hydrofluoroalkane</keyword>
  <keyword>Long-acting beta-agonist</keyword>
  <keyword>Fixed-dose combination therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

